| |
|
|
| |
You are here: Home: BCU NSABP Symposium : Agenda |
|
| |
|
|
| |
NSABP MEETING AGENDA Targeted Adjuvant Systemic
Therapy of Breast Cancer
Current and Future Role
of Trastuzumab* |
| |
| Dr Wolmark |
Introduction
|
| Dr Love |
Education objectives, clinical cases
for discussion and current patterns
of care in the community
|
| Dr Romond |
Combined analysis of NSABP-B-31
and NCCTG-N9831 —
Doxorubicin and cyclophosphamide
followed by paclitaxel with or without
trastuzumab as adjuvant therapy
for patients with HER2-positive
operable breast cancer.
|
|
| Dr Slamon |
BCIRG 006 — A randomized
Phase III trial comparing AC T
versus ACTH versus TCH
in HER2-positive, node-positive
or high-risk, node-negative
breast cancer
|
| Dr Leyland-Jones |
HERA trial — A randomized
comparison of one year versus
two years versus no trastuzumab
in women with HER2-positive
breast cancer who have completed
adjuvant chemotherapy
|
| Dr Kaufman |
NCCTG-N9831 — Sequential
versus concurrent trastuzumab
and chemotherapy
|
| Dr Geyer |
NSABP-B-31 cardiac toxicity data
|
|
|
 |
CHAIRMAN
Neil Love, MD |
| |
|
 |
CO-CHAIRMAN
Norman Wolmark, MD |
| |
|
|
| FACULTY |
|
 |
Charles E Geyer Jr, MD |
 |
Brian Leyland-Jones, MD, PhD |
 |
Edward H Romond, MD |
 |
Dennis J Slamon, MD, PhD |
 |
Peter A Kaufman, MD |
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
